🇺🇸 FDA
Patent

US 9057069

Compositions and methods for inhibiting expression of Eg5 gene

granted A61PA61P35/00A61P43/00

Quick answer

US patent 9057069 (Compositions and methods for inhibiting expression of Eg5 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P35/00, A61P43/00